-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $572

Benzinga·11/10/2025 15:31:13
Listen to the news
RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $589 to $572.